Canada Pension Plan Investment Board Purchases 89,235 Shares of Moderna, Inc. (NASDAQ:MRNA)

Canada Pension Plan Investment Board raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 24.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 454,407 shares of the company's stock after purchasing an additional 89,235 shares during the period. Canada Pension Plan Investment Board owned approximately 0.12% of Moderna worth $18,894,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in shares of Moderna during the 4th quarter valued at about $37,000. Venturi Wealth Management LLC grew its position in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new stake in Moderna during the 4th quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRNA has been the subject of several research reports. Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. JPMorgan Chase & Co. cut their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus price target of $58.70.

Moderna Stock Down 0.6 %

Shares of MRNA traded down $0.17 during mid-day trading on Friday, hitting $27.22. 7,714,270 shares of the company's stock were exchanged, compared to its average volume of 7,343,319. The firm has a market cap of $10.52 billion, a price-to-earnings ratio of -2.93 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The stock's 50-day simple moving average is $30.19 and its 200-day simple moving average is $38.64.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.